Novel risk scoring system for patients with metastatic castration-resistant prostate cancer treated with lutetium-177-PSMA-617.

Oncologist · 2026 · PMC13395084 · PMID 42434975

Europe PMC DOI

hedged sentence

0.0990

closest p · 2.0× alpha

0.0990

boldest claim

The sentences

a nonsignificant trendP = .099so close (0.05 < p ≤ 0.1)

Compared with patients with a BMI ≥ 30, patients with a BMI < 25 had lower odds of achieving a PSA50 response (odds ratio [OR] = 0.28, 95% confidence interval [CI], 0.10-0.78, P = .015), and patients with a BMI of 25 to <30 demonstrated a nonsignificant trend toward lower odds of a PSA50 response (OR = 0.45, 95% CI, 0.17-1.16, P = .099).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.